US › Healthcare

Bicycle Therapeutics Ltd (BCYC)

US · Healthcare · Biotechnology

$3.94+1.81%
Last close · 2026-08-04

Latest quarter · ended 2026-06-30

Revenue
$629,000
Revenue YoY
-78.5%
Net profit
$-50.3M
Profit YoY
+36.2%
EPS
$-0.72
EPS estimate
$-0.37
Net margin
-8,002.1%

EPS came in at -0.72 against a street estimate of -0.37 — a miss of 94.6%.

Key statistics

Market cap
$269.5M
Forward P/E
0.0
P/B
0.53
Book value
$7.95
EPS (TTM)
$-2.73
52-week high
$9.16
52-week low
$3.75
50-day MA
$4.20
200-day MA
$5.61
Beta
1.55

Analyst view

Analysts rate Bicycle Therapeutics Ltd a buy (10 buy, 3 hold, 0 sell out of 13) with an average price target of $9.86.

Shareholding

Insiders
4.47%
Institutions
73.90%

Largest institutional holders

FundStake
Baker Bros Advisors LP15.59%
FCPM III SERVICES BV4.97%
Armistice Capital, LLC4.87%
Long Focus Capital Management, LLC4.74%
Acadian Asset Management LLC2.82%
Siren, L.L.C.2.24%
GSK PLC2.19%
Principal Financial Group Inc1.68%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Bicycle Therapeutics Ltd — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.